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Abstract: Islet transplantation into subcutaneous polymer scaffolds has shown to successfully induce
normoglycemia in type 1 diabetes models. Vascularization of these scaffolds is imperative for optimal
control of glucose levels. We studied the effect of the vascular stimulator hydrogen sulfide (H2S) on
the degree of vascularization of a scaffold and the role of the immune system in this process. Scaffolds
were subcutaneously implanted in immunocompetent C57BL/6 and immunocompromised nude
mice. Mice received twice-daily intraperitoneal injections of the fast-releasing H2S donor sodium
hydrosulfide (NaHS, 25 or 50 µmol/kg) or saline for 28 days. After 63 days the vascular network was
analyzed by histology and gene expression. Here we showed that the vascularization of a subcutaneous
scaffold in nude mice was significantly impaired by H2S treatment. Both the CD31 gene and protein
expression were reduced in these scaffolds compared to the saline-treated controls. In C57BL/6
mice, the opposite was found, the vascularization of the scaffold was significantly increased by H2S.
The mRNA expression of the angiogenesis marker CD105 was significantly increased compared to
the controls as well as the number of CD31 positive blood vessels. In conclusion, the immune system
plays an important role in the H2S mediated effect on vascularization of subcutaneous scaffolds.
Keywords: immune system; vascularization; hydrogen sulfide; subcutaneous scaffolds
1. Introduction
Transplantation of insulin-producing cells, such as the islets of Langerhans, is a promising
treatment for type 1 diabetes. It provides continuous regulation of the blood glucose levels and
therefore results in stable glycemic control and the reduction of secondary complications such as
cardiovascular diseases, retinopathy, and nephropathy. Currently, pancreatic islets are infused via the
portal vein into the liver and this results in 100% insulin independency after 1 year [1], but due to
multiple factors, the islets do not survive long-term since insulin independency decreases to less than
50% after 5 years. There are many indications that the liver is partly responsible for this and therefore
may not be the optimal islet transplantation site [2]. The microenvironment of the liver is detrimental
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for islet survival due to the presence of specific liver immune cells, the induced blood-mediated
inflammatory response, and the exposure to antigens and toxins because of the gut-liver axis [2].
Since the human body does not provide a better islet transplantation site, engineering an artificial
islet transplantation site, also called a scaffold, that mimics the pancreatic microenvironment, could
be a solution [3]. Such a scaffold could be implanted under the skin, making transplantation of
insulin-producing cells only a minor surgical procedure and allowing for retrieval of these cells.
Retrievability might be mandatory with replenishable cell sources, like stem cells, that still have some
insufficiencies such as incomplete maturation, uncontrolled proliferation, aberrant protein expression,
and tumorigenic potential [4].
An artificial islet transplantation site with proven success is the subcutaneously implanted poly
(D,L-lactide-co-ε-caprolactone) (PDLLCL) scaffold [5,6]. After transplantation of 800 islets into this
scaffold, 80% of the mice became normoglycemic, whereas islet transplantation under the unmodified
skin without the scaffold did not result in normoglycemia in any of the mice. Crucial for islet function
is their vascularization. This is not only important for the supply of oxygen and nutrients, but also for
their ability to quickly respond to glucose changes in the blood. In the native pancreas, islets receive
10–20% of the pancreatic blood supply, while the total islet mass is just 2% [7]. Furthermore, the number
of capillaries in the islets is ten times higher than in the rest of the pancreas [7], and these capillaries are
20–30% wider and form a glomerular-like network around the insulin-producing cells [8]. However,
during islet isolation from donor pancreata, the islet vasculature is disrupted. Therefore, improving
the vascularization of islet transplantation scaffolds would further increase transplantation outcomes.
The gasotransmitter hydrogen sulfide (H2S) has been reported to be involved in the homeostasis
of the cardiovascular system [9]. In vitro H2S stimulates endothelial cell proliferation, migration,
and tube formation [10,11]. In vivo it promotes blood vessel sprouting and growth in chicken
chorioallantoic membranes [11] and a study in mice showed increased angiogenesis in subcutaneous
Matrigel plugs [10]. Therefore, we aimed to improve the vascularization of our polymer scaffold with
the use of H2S. Since H2S is also known to influence the immune system [9], we studied the scaffold
vascularization in both immunocompromised and immunocompetent mice. Vascularization was
investigated by performing immunohistochemistry and gene expression analysis of several vascular
markers. This study will support determination of the optimal preimplantation period needed for the
development of a vascular network before introduction of islets.
2. Materials and Methods
2.1. Experimental Design
Immunocompromised athymic nude mice (Foxn1nu) and immunocompetent C57BL/6 mice were
used to test the effect of H2S on vascularization of PDLLCL scaffolds. Scaffolds were subcutaneously
implanted on the back of the mice. From the day of implantation, the mice received an intraperitoneal
injection of the fast-releasing H2S donor sodium hydrosulfide (NaHS) twice daily until one month
after implantation. One group of mice (n = 6) received a low dose of NaHS (25 µmol/kg), the other
group (n = 6) received a high dose of NaHS (50 µmol/kg), and mice receiving saline injections served
as a control group (n = 6). To allow the vascular network to stabilize, the scaffolds were not directly
removed after finishing the H2S treatment period. Non-invasive, in vivo oxygen measurements in the
nude mice showed no statistical differences between the groups and it seemed to stabilize after 63 days
(data not shown). Therefore, scaffolds were removed for histological analysis and quantification of
vascularization by real time reverse transcription polymerase chain reaction (RT-PCR) after 63 days.
2.2. Scaffold Preparation
Scaffolds were prepared from a 4% (w/v) PDLLCL solution in chloroform (Sigma-Aldrich,
Zwijndrecht, The Netherlands). The PDLLCL solution was thoroughly mixed with sodium chloride
particles (Sigma-Aldrich) of 250–425 µm (10:1 w/w) in order to create a porous structure. This solution
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was transferred into sterile glass petri dishes to allow the solvent to evaporate. To remove the salt
particles, the polymer sheet (5 mm thick) was extensively washed with sterile H2O. The polymer sheet
was casted and resized, resulting in 10 mm by 15 mm devices. The scaffolds were stored in 70% ethanol
for several days to sterilize them before implantation. Fibrin was added to the scaffold on the day
of implantation. Briefly, a 2 mg/mL fibrinogen solution (Sigma-Aldrich) was mixed with 100 U/mL
thrombin IIa (Sigma-Aldrich) (100:1) and transferred into the pores of the scaffolds.
2.3. Animals
The University of California Institutional Animal Care and Use Committee at the University of
Irvine approved all described animal procedures (IACUC # 2008-2850). Scaffolds were implanted
in 8-week old male athymic nude mice (total of 18 mice; Charles River, Wilmington, NC, USA) and
C57BL/6 mice (total of 18 mice; Charles River). Animals were housed at the University of California
Irvine animal facility and maintained under 12-hour light/dark cycles with ad libitum access to water
and standard chow.
2.4. Implantations and NaHS Injections
Mice were anesthetized by placing them individually in an induction chamber infused with 4%
isoflurane (Patterson Veterinary, Greeley, CO, USA) mixed with 100% oxygen (flow rate 2 L/min).
After induction, the mice were placed on a homeothermic blanket with an anesthesia facemask and the
anesthesia was reduced during surgery to 2%. A small incision was made in the skin, after which a
subcutaneous pocket was created on the back of the mice to implant the PDLLCL scaffolds. The skin
was closed using skin staples (Cellpoint Scientific, Gaithersburg, MD, USA). All mice received ibuprofen
water (Banner Pharmacaps, High Point, NC, USA; 0.2 mg/mL) as an analgesic post-surgery for two
days. Since H2S is a gas, a NaHS solution (Sigma-Aldrich) was used as a H2S donor. The solution was
prepared shortly before injection by dissolving NaHS in saline. From the day of implantation, the mice
received an intraperitoneal injection of NaHS or saline twice daily until 28 days after implantation of
the scaffolds. The injected volume, based on the dose and body weight, ranged between 250–350 µL
for the H2S groups. Control mice received a similar volume of saline.
2.5. Histology
The scaffolds were removed 63 days after implantation. Half of the scaffold was processed for
histology (n = 6 of each experimental group) and the other half was used for RT-PCR (n = 6 of each
experimental group; described below). For histology, scaffolds were fixed in 2% paraformaldehyde
and processed for paraffin embedding. Paraffin sections were stained for the endothelial marker
CD31 (1:200; R&D Systems, Abingdon, UK) and the monocyte and macrophage marker MOMA-2
(1:50; Abcam). Briefly, for the CD31 staining, antigen retrieval was performed by incubation in 10
mM citrate buffer (pH 6.0) for 15 min at 100 ◦C. This was followed by blocking with 5% donkey
serum (Sigma-Aldrich) and an overnight incubation with the primary antibody. The secondary
donkey anti-goat alkaline phosphatase conjugated antibody (1:100; Abcam) was applied for 45 min.
For the MOMA-2 staining, a 15 min incubation with 0.1% trypsin (in 6.8 mM 0.1% calcium chloride
and 0.1 M Tris(hydroxymethyl)-aminomethane-hydrogen chloride, pH 7.8) at 37 ◦C was performed
for antigen retrieval, followed by a blocking step with 5% rabbit serum (Agilent Technologies).
After overnight incubation with the primary antibody, a biotin conjugated rabbit anti-rat antibody
(1:100; Vector Laboratories, Peterborough, UK) was added for 45 min. Subsequently, sections were
incubated for 45 min with a streptavidin-alkaline phosphatase conjugate (1:100; Southern Biotech).
Alkaline phosphatase activity of both above-mentioned stainings was demonstrated by incubating the
sections for 10 min with SIGMAFASTTM Fast Red. A short incubation with hematoxylin was used
as counterstain.
All stained sections were scanned with a Hamamatsu Nanozoomer slide scanner (Hamamatsu,
Almere, The Netherlands). Scans were analyzed using Aperio ImageScope software (Leica Microsystems
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B.V., Rijswijk, The Netherlands). The number of CD31 positive structures were counted and corrected
for the measured scaffold area (mm2). For the MOMA-2 staining, the number of strong positive pixels
was corrected for the measured scaffold area (mm2). The fold change of both stainings was calculated
relative to the control. Pictures were taken using a Leica DM 2000 LED microscope with a Leica DFC
450 camera (Leica Microsystems B.V.).
2.6. RT-PCR
To quantify gene expression in the scaffolds, half of each individual scaffold at day 63 was
processed for RT-PCR. Briefly, total RNA was isolated using Trizol according to manufacturer’s
protocol (Invitrogen; Thermo Scientific, Landsmeer, The Netherlands). The RNA concentration was
determined using a NanoDrop 1000 spectrophotometer (NanoDrop products, Wilmington, NC, USA).
cDNA was reverse transcribed using a SuperScript® III Reverse Transcriptase kit according to the
instructions of the manufacturer (Life technologies). RT-PCR was conducted using ViiATM Real Time
PCR system (Life technologies) with primer and probe sets (TaqMan Gene Expression Assays) for
several vascularization genes (CD31, VEGFa, VE-cadherin, CD105 (endoglin), angiopoietin 1 and 2)
purchased from Thermo Scientific (Table 1) and qPCR Mastermix Plus (Eurogentec, Seraing, Belgium).
Reactions were performed at 50 ◦C for 2 min, 95 ◦C for 10 min, 95 ◦C for 15 s, and 60 ◦C for 60 s,
repeating these last two steps for 40 cycles. Delta Ct values were calculated and normalized against
the expression of the housekeeping gene GAPDH. Delta Ct values were used to determine the fold
change of the H2S treated groups compared to the control group.









2.7. Blood Vessel Functionality Tests
To test the functionality of the blood vessels, 3 out of the total of 6 mice in each C57BL/6 group were
used for in vivo oxygen measurements and lectin perfusion. The oxygen measurements were done with
the Microx 4 precision sensing system for oxygen profiling from PreSens (Regensburg, Germany) at
day 7, 14, 28, and 63 after implantation. To this end, the oxygen probe was placed in a minimal invasive
manner in the scaffold for 10 min while the animal was anesthetized with isoflurane (as described
above for the implantations). Furthermore, mice were perfused with 200 µL DyLight 649 labeled
Lycopersicon Esculentum (Tomato) lectin (Vector Laboratories; Brunschwig Chemie, Amsterdam,
The Netherlands) via a single injection into the carotid artery under isoflurane anesthesia (as described
above for the implantations) at day 63. Lectin was allowed to circulate for 15 min after which the
vasculature was flushed with saline. Explanted scaffolds were fixed in 2% paraformaldehyde and
confocal microscopy (Leica SP8; Leica Microsystems B.V.) was used to obtain images of the lectin
staining. Acquired images were analyzed with Image J [12] as described by Weaver et al. in 2018 [13].
Briefly, the background fluorescent signal was removed and the number of branches and junctions, the
maximal branch length, and the average branch length were measured using the skeleton macro plugin.
2.8. Statistics
Statistical analysis was carried out in GraphPad Prism [14]. A Shapiro–Wilk normality test was
performed to test the data for normality. To test differences between the groups, a one-way ANOVA
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with a post-hoc test was applied, and p-values < 0.05 were considered significant. The data are
presented in mean ± standard error of mean.
3. Results
3.1. Vascularization of the Scaffolds in C57BL/6 Mice not Affected by H2S
Since the skin is less vascularized than the native pancreas, vascularization of the subcutaneous
implanted scaffold is imperative for transplantation outcomes and efficacy [15]. Previous studies of
others showed that H2S enhances vascularization [10,11]. Cai and coworkers [10] showed increased
neovascularization of a subcutaneous placed Matrigel plug after 7 days of intraperitoneal injections
with NaHS (10–50 µmol/kg). This was studied in immunocompetent C57BL/6 mice. Therefore,
to determine the effect of H2S on vascularization of subcutaneous scaffolds, they were implanted
in C57BL/6 mice for 63 days and processed for RT-PCR and histology of vascularization markers.
However, H2S treatment did not stimulate vascularization at the gene level in the immunocompetent
C57BL/6 mice. No significant differences were found between the groups in the gene expression of
endothelial marker CD31 (Figure 1A). Furthermore, the same was observed for the gene expression of
other vascularization markers such as VE-cadherin, angiopoietin 1, and angiopoietin 2 showing that
H2S treatment did not significantly increase their expression (Table 2). Only the mRNA expression of
angiogenesis marker CD105 was significantly upregulated in the low H2S group (fold change 1.8 ± 0.4)
compared to the untreated control (Figure 1B).
At the protein level, both H2S dosages significantly increased the number of CD31 positive blood
vessels in C57BL/6 mice (Figure 1C–F). The low dose showed an increase of vascularization with a fold
change of 2.4 ± 0.1 compared to 1.0 ± 0.1 in the untreated control group. In addition, the fold change of
the high dose group was significantly increased (2.6 ± 0.2) compared to the control.
To get more insight into the extent that the changes in vascularization by H2S improved the
available amount of oxygen within the subcutaneous scaffolds, we measured the in vivo oxygen
percentage (Figure 2). These measurements showed a statistically significant decrease in oxygen
percentage by the low H2S treatment at day 28 (p < 0.05) compared to both the control and the high
H2S treatment. The oxygen percentage in the low H2S group was 13.0% ± 1.2, whereas the oxygen
percentages in the control and high H2S groups were respectively 18.5%± 0.6 and 16.0%± 0.5. However,
this effect was not present any more at day 63. Although we found increased amounts of blood vessels,
the amount of available oxygen does not seem to be improved. In addition, the functionality of the
blood vessels was further tested by using lectin infusion. The lectin labeling of blood vessels showed
that in all groups blood vessels within the scaffolds are well perfused (Figure 3A–C), but no statistical
differences were found between the groups in the number of branches or junctions (Figure 3D).
In addition, no differences were observed in the average vascular branch length, but the maximal
vascular branch length is significantly longer after treatment with the low dose of H2S (Figure 3E).
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Figure 1. Gene and protein expression of vascularization markers after 63 days of implantation in
C57BL/6 mice. There were no significant changes in the mRNA expression of CD31 (A), but the
expression of CD105 statistically significantly increased after treatment with the low H2S dose (B; n = 6).
Many CD31 positive cells (pink color/arrowheads) were found in the control (C), low (D) and high (E)
H2S treated groups. (F) depicts the quantification of the CD31 staining; the number of blood vessels
per mm2 of scaffold was normalized to the control (n = 6). Mean and standard error of the mean are
plotted; a statistical analysis was carried out using a one-way ANOVA with a Tukey post-hoc test,
p < 0.05 (*), p < 0.0001 (***).
Table 2. Gene expression of vascularization markers after 63 days of implantation in C57BL/6 mice.
Data is expressed as mean fold change ± standard error of the mean (n = 6). A one-way ANOVA with
Tukey post-hoc test (p < 0.05) did not show any significant differences between the groups.
Gene Control Low H2S High H2S
VEGFa 1.0 ± 0.1 0.9 ± 0.1 1.1 ± 0.01
VE-Cadherin (CDH5) 1.1 ± 0.2 1.7 ± 0.4 1.9 ± 1.0
Angiopoietin 1 1.1 ± 0.3 1.3 ± 0.4 1.6 ± 0.6
Angiopoietin 2 1.0 ± 0.1 1.1 ± 0.4 1.7 ± 0.5
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Figure 2. Oxygen percentage within subcutaneous scaffolds of C57BL/6 mice. After implantation of the
scaffolds and start of the H2S treatment (grey area) the oxygen percentage was measured on day 7,
14, 28, and 63 with the Microx 4 PreSens system. Mean and standard error of the mean are plotted
(n = 3); a statistical analysis was carried out using a two-way ANOVA with a Bonferroni post-hoc test,
p < 0.05 (*).
Figure 3. Lectin labeling of blood vessels after 63 days of implantation in C57BL/6 mice and H2S
treatment. Lectin labeling (red) was found in the control (A) group and in the low (B), and high (C) H2S
treated groups. (D,E) depict the quantification of lectin labeling. Mean and standard error of the mean
are plotted (n = 3); a statistical analysis was carried out using a one-way ANOVA with a Dunnett’s
post-hoc test, p < 0.05 (*).
To gain more insight into the possible mechanisms underlying the vascularization after H2S
treatment, monocyte and macrophage staining was performed (Figure 4). This showed that monocytes
and macrophages were reduced after 63 days of implantation in C57BL/6 mice with H2S treatment
compared to untreated controls (Figure 4). The fold-change for the low and high H2S group was
respectively 0.2 ± 0.1 and 0.4 ± 0.2.
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Figure 4. Staining of monocytes and macrophages after 63 days of implantation in C57BL/6 mice.
Monocytes and macrophages are stained in pink for the control group (A), low dose H2S (B), and
high dose H2S (C). (D) depicts the quantification of the staining; the number of strong positive pixels
per mm2 of scaffold was normalized to the control (n = 6). Mean and standard error of the mean are
plotted; a statistical analysis was carried out using a one-way ANOVA with a Dunnett’s post-hoc test,
p < 0.05 (*).
3.2. Vascularization of the Scaffolds in Nude Mice Impaired by H2S
The reduced influx of monocytes and macrophages in the C57BL/6 mice in response to H2S
indicates a role for the immune system. Therefore, to investigate if the immune status of the animal
plays a role in the effect of H2S, we repeated this study in nude mice. Again after 28 days of treatment
and 63 days of implantation, the scaffolds were examined by gene expression analysis and histology.
Unlike in the C57BL/6 mice, statistically significant differences were found in the mRNA expression
levels of CD31 (Figure 5A). In contrast to our hypothesis, H2S did not stimulate vascularization.
Compared to the control group, the mRNA expression of the endothelial marker CD31 was significantly
reduced by 50% when treated with a low dose of H2S (fold change of 0.6 ± 0.02, p < 0.001). Treatment
with the high H2S dose did not result in a significant decrease (fold change of 0.9 ± 0.1). Furthermore,
the gene expression of other vascularization markers such as VEGFa and VE-cadherin decreased in
a dose-dependent manner with H2S treatment, whereas the expression of angiopoietin 1 increased
in a dose-dependent manner. The expression of angiopoietin 2 and the angiogenesis marker CD105
remained unchanged (Table 3). This is in contrary with the results from the C57BL/6 mice, where only
CD105 was found to significantly increase after treatment with H2S.
Immunohistological staining of CD31 showed a similar trend in the protein level (Figure 5B–E)
as was observed for mRNA expression. The treatment with H2S resulted in a decreased number of
blood vessels, whereas the C57BL/6 mice showed a significant increase of blood vessels after H2S
treatment. Treatment with the low dose resulted in a statistically significant decrease (p < 0.05) of
CD31 positive structures with a fold change of 0.4 ± 0.1. The high dose also showed a decrease, the
number of blood vessels was halved in these scaffolds (fold change 0.5 ± 0.2) compared to the controls
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(p = 0.07). We observed in the raw data of the control groups a higher number of CD31 positive blood
vessels per mm2 of scaffold, 40.5 ± 7.5 and 11.0 ± 1.2, in the nude mice compared to the C57BL/6 mice,
respectively (Figure S1A). In addition, H2S did not influence the in vivo oxygen availability within the
scaffolds in the nude mice (Figure S2).
Figure 5. Gene and protein expression of vascularization maker CD31 after 63 days of implantation in
nude mice. The expression of CD31 statistically significantly decreased after treatment with the low H2S
dose (A; n = 6). Many CD31 positive cells (pink color/arrowheads) were found in the control (B) group,
the presence of CD31 was decreased in the low (C) and high (D) H2S treated groups. (E) depicts the
quantification of the CD31 staining; the number of blood vessels per mm2 of scaffold was normalized to
the control (n = 6). Mean and standard error of the mean are plotted; a statistical analysis was carried
out using a one-way ANOVA with a Tukey post-hoc test, p < 0.05 (*), p < 0.001 (**).
Biomolecules 2020, 10, 722 10 of 14
Table 3. Gene expression of vascularization markers after 63 days of implantation in nude mice. Data
are expressed as mean fold change ± standard error of the mean (n = 6). A one-way ANOVA with
Tukey post-hoc test (p < 0.05) did not show any significant differences between the groups.
Gene Control Low H2S High H2S
VEGFa 1.0 ± 0.1 1.0 ± 0.2 0.6 ± 0.04
VE-Cadherin (CDH5) 1.0 ± 0.1 0.9 ± 0.1 0.8 ± 0.1
Angiopoietin 1 0.9 ± 0.1 1.3 ± 0.2 1.5 ± 0.2
Angiopoietin 2 1.0 ± 0.1 0.9 ± 0.03 1.0 ± 0.2
CD105 (Endoglin) 1.0 ± 0.1 1.1 ± 0.1 1.0 ± 0.1
In contrary with the results of the C57BL/6 mice, the intensity of the monocyte and macrophage
staining was shown to increase in a statistically significant and dose-dependent manner (Figure 6).
In the control scaffolds, monocytes and macrophages are present, but this increased twofold with the
low dose H2S treatment (1.9 ± 0.5). The high H2S treatment even further increased the intensity of the
monocyte and macrophage staining with a fold change of 4.2 ± 0.5. In addition, the literature states
that nude mice have an exaggerated macrophage response [16]. In accordance with the literature,
we observed a higher number of MOMA-2 positive pixels per mm2 of scaffold, 223,358 ± 71,364 and
72,532 ± 31,919, in the nude mice of the control groups compared to the C57BL/6 mice, respectively
(Figure S1B).
Figure 6. Staining of monocytes and macrophages after 63 days of implantation in nude mice.
Monocytes and macrophages are stained in pink for the control group (A), low dose H2S (B), and high
dose H2S (C). (D) depicts the quantification of the staining; the number of strong positive pixels per
mm2 of scaffold was normalized to the control (n = 6). Mean and standard error of the mean are plotted;
a statistical analysis was carried out using a one-way ANOVA with a Tukey post-hoc test, p < 0.05 (*),
p < 0.001 (**).
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4. Discussion
The formation of a stable vascular network within a subcutaneous scaffold is a complex process; it
involves, among others things, angiogenic signals, migration and proliferation of endothelial cells, and
formation of vascular structures. The exact role of H2S in the process of angiogenesis is still a subject of
debate. There are only a few published in vitro studies [10,11] and even less in vivo data is available [10].
Here we investigated the role of the immune system on the angiogenic potential of H2S. In nude mice,
which lack T cells and therefore have a deficient T-cell mediated immune response, we showed that
intraperitoneal injections of a fast-releasing H2S donor resulted in significantly reduced vascularization
of subcutaneously implanted scaffolds compared to saline-treated controls. In C57BL/6 mice with a
fully functional immune system, the opposite was found; the vascularization of our subcutaneous
scaffold was significantly increased after treatment with the fast-releasing H2S donor. This was reflected
in the increased angiogenesis gene CD105 and the increased number of blood vessels at the protein
level. The difference between both animal strains indicates that the T cells are involved in the H2S
angiogenic potential. Yang and coworkers showed that H2S activates DNA methylation of Foxp3 T
regulatory cells to promote immune tolerance [17], indicating an anti-inflammatory environment in
the mice with a normal T-cell response. Differences in the immune response were also found between
the immunocompetent and immunocompromised mouse model in the presence of monocytes and
macrophages. This might be related to the fact that we used a setting with biomaterials that provoke a
foreign body response in the first weeks after implantation [6]. Monocytes, macrophages, and foreign
body giant cells play an important role in initiating the foreign body response, followed by fibroblast
infiltration into the implanted scaffold. The foreign body response often occurs in the first three weeks
after implantation. After that, wound healing occurs, accompanied by neovascularization of the
scaffold [18]. We observed an increased presence of monocytes and macrophages in the nude mice in
the H2S treated groups after 63 days suggesting that the foreign body response is still ongoing, while
our previous study showed that this was dampened between 2 and 4 weeks [6]. H2S is associated
with both pro- and anti-inflammatory responses [19–21]. During a pro-inflammatory response, it
has been found that H2S increases the production of TNF alpha and activates monocytes [19,20].
The monocytes and macrophages are known to play an important role in tissue regeneration; for
example, both these cells types influence vascular remodeling [22]. The increase in monocytes and
macrophages could therefore be a factor in the observed decrease of scaffold vascularization in the
nude mice. Since we observed impaired vascularization, we hypothesize that, in our study, H2S
promotes the differentiation of pro-inflammatory M1 macrophages [23]. These M1 macrophages could
induce epithelial to mesenchymal transition (EMT) [24], which might explain the reduced number of
endothelial cells in nude mice. In contrary, it seems that H2S in C57BL/6 mice has an anti-inflammatory
effect, since a reduced number of macrophages and monocytes was found. However, to confirm this
hypothesis, further experiments are needed and it remains to be elucidated how H2S affected different
lymphoid cells in order to pro-long this effect until 35 days after the last NaHS injection.
Our data supports the view that H2S has angiogenic potential in an immunocompetent environment
and this effect seems to be concentration dependent. Here we found that the effect of H2S was more
profound in both animal strains when using the lower dosage. Other studies have also shown
that the lower dosages of H2S are more effective; higher H2S dosages seem to fail in promoting
vascularization [10,11]. Cai and coworkers [10] also tested H2S in a biomaterial setting and showed
increased neovascularization of a subcutaneous placed Matrigel plug after 7 days of intra peritoneal
injections with NaHS (10–50 µmol/kg). In addition, they also found that the H2S effect was lost when
the dose was higher than 200 µmol/kg NaHS. Several other in vivo studies in other settings without
a foreign body response against a biomaterial have shown that H2S induces angiogenesis in highly
inflamed tissues. For example, daily H2S treatment can selectively restore chronic ischemic tissue
function [25,26] and improve ventricular remodeling after heart failure [27].
In this study, we did not distinguish between the direct and indirect effects of H2S. H2S itself
has a broad range of effects depending on several factors, such as concentration, tissue type, and
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inflammatory status. But when H2S reacts with oxygen, polysulfides are formed and these can also
have a broad range of physiological functions [28]. Furthermore, NaHS does not provide long-term
controlled release of H2S. This burst release could have side effects like local cytotoxicity or limiting
H2S effects on vascularization. To this end, clinical application would benefit from a quick noninvasive
method to measure H2S concentration and a H2S donor that provides controlled release, like natural or
synthetic donors [29]. However, the results might be different with a slow-releasing H2S donor.
5. Conclusions
Our findings demonstrate that the immune system plays an important role in the effect of
H2S treatment on vascularization of subcutaneous scaffolds. In a compromised immune system,
H2S decreases vascularization, whereas in a normal working immune system, it can stimulate
vascularization. These observations suggest that H2S may be beneficial for the outcome of islet
transplantation in a subcutaneous scaffold as treatment for type 1 diabetes, but at the same time our
data warrant care in choosing correct models for studying vascularization processes as efficacy of H2S
in immunocompromised animals was lower than in fully immunocompetent animals.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/5/722/s1,
Figure S1: Number of CD31-positive blood vessels and MOMA-positive pixels per mm2 scaffold after 63 days.
Mean and standard error of mean are plotted (n = 6). Statistical analysis using a Mann Whitney test (p < 0.05)
showed significant differences (*) between the nude and C57BL/6 mice for the CD31 staining, but not for the
MOMA-2 protein expression, Figure S2: Fall time during dynamic inhaled gas test. During the dynamic inhaled
gas test anesthetized mice start with breathing 20% of oxygen, with a custom-made sensor the signal from the
oxygen sensitive tubes in the scaffold is measured when changing from 20% to 100% of oxygen. The time until a
plateau occurs at 100% was reported as the fall time, which is an indication of the vascularization status of the
scaffold. Mice were treated with saline (control), low dose of H2S, and high dose of H2S during 28 days (grey
area). Mean and standard error of mean are plotted (n = 6); statistical analysis was carried out using a two-way
ANOVA with a Bonferroni post-hoc test.
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